Treating serious infections
Bacterial resistance is increasing worldwide, making treatment options more limited. The World Health Organization (WHO), in 2010, characterized bacterial resistance as one of the three greatest threats to human health. In a 2013 report, “Antibiotic Resistance Threats in the United States,” the U.S. Centers for Disease Control and Prevention (CDC) warned of the complex problem of antibiotic resistance and the potentially catastrophic consequences of inaction.
When first-line and then second-line antibiotic treatment options are limited by resistance or are unavailable, healthcare providers are forced to use antibiotics that may be more toxic to the patient and frequently more expensive and less effective. The development of new antibiotics to meet this threat is a matter of urgency. Nabriva is developing novel antibiotics, with a focus on pleuromutilins, which is a new class of antibiotics for systemic administration in humans.